Ekspresi Topoisomerase II α pada Diffuse Large B Cell Lympho-ma dan Hubungannya dengan Respon Terapi

Indri Windarti , Endang SR Hardjolukito, Maria Francisca Ham, Tubagus Djumhana Atmakusuma, Wulyo Rajabto

Research output: Contribution to journalArticlepeer-review


Background Standard of chemotherapy for Diffuse Large B Cell Lymphoma (DLBCL) is a regimen containing doxorubicin. Doxorubicin is a component of anthracycline based chemotherapy that work as anti Topoisomerase II (Top2). Previous study on tumor cell lines showed that high expression of Topoisomerase II α (Top2A) was related to higher sensitivity to anthracycline as well. The aim of this study is to know the expression of Top2A and its relation to treatment response. Methods A cross-sectional study on 38 which DLBCL cases CD20 positive that have been treated with at least 4 cycles of chemotherapy. The immunohistochemical staining was performed on Top2A protein assesed using H-score. Results Expression of Top2A protein were found in 37 of 38 (97%) cases (H-score range: 101.5-215.0 and median 124.1). Value Top2A was defined as high if H-score more was higher than 124.1. Statistical analysis showed that Top2A expression in DLBCL was not significantly related to treatment response (p=0.670). Conclusion There was no significant relation between Top2A expression and treatment response. Top2A expression in DLBCL cannot be used as a predictor of treatment response.
Original languageEnglish
JournalMajalah Patologi Indonesia
Issue number3
Publication statusPublished - 2013


Dive into the research topics of 'Ekspresi Topoisomerase II α pada Diffuse Large B Cell Lympho-ma dan Hubungannya dengan Respon Terapi'. Together they form a unique fingerprint.

Cite this